AI Summary
The content provided discusses peritoneal effusion, which is an uncommon adverse effect of selective RET inhibitors. Chylous effusion, a rare side effect, can occur during treatment with multikinase inhibitors or selective RET tyrosine kinase inhibitors. The pleura, peritoneum, or both can be affected, with the peritoneum being less common. Selpercatinib and MKIs were identified as the most frequent causes of chylous effusion. No confirmed cases were observed with pralsetinib, but there have been cases of chylous ascites in RET rearranged NSCLC patients receiving pralsetinib.
Chylous effusion is a rare side effect observed during treatment with multikinase inhibitors (MKI) or selective RET tyrosine kinase inhibitors (TKIs) [1]. Pleura (12/22; 54%), peritoneum (5/22; 23%), or both (5/22; 23%) were common sites for chylous effusion. Selpercatinib (15/217; 7%) and MKIs (7/7371; <1%) were the most frequent causes. No confirmed effusion cases were observed with pralsetinib, but two RET rearranged NSCLC patients on pralsetinib had chylous ascites in a recent case series [2].